ASX ANNOUNCEMENT

30 October 2026

Quarterly Activities Report

For the quarter ended 30 September 2026

QUARTER HIGHLIGHTS

— Commercial pathway operating end to end: patient education, telehealth consultation, pharmacy fulfilment and discreet home delivery are now fully operational for the Company's Libbo® erectile dysfunction oral film, with products supplied to patients ahead of full product registration.

— Pilot clinical study for Libbo® progressing: dosing is targeted for Q4 2026, subject to completion of the remaining testing and regulatory steps, with pilot data anticipated in early 2027.

— Libbo® path to registration: pilot data anticipated in early 2027 will inform the design of the pivotal bioequivalence study that underpins the Company's registration pathway, with study timing to be confirmed as the pilot progresses.

— Reformulation pipeline progressing across men's health and cardio-metabolic programs.

— Closing cash of $836,000 at 30 September 2026 with no borrowings.

EVE Health Group Limited (ASX: EVE, EVE or the Company), an Australian life sciences company, provides its activities update for the quarter ended 30 September 2026. During the quarter, EVE's patient pathway for its erectile dysfunction oral film operated end to end, its reformulation pipeline continued to progress across men's health and cardio-metabolic programs, and the Company prepared for its pilot clinical study, with dosing targeted for Q4 2026. The pilot is an important early step in the clinical milestones that underpin EVE's path to full product registration.

COMMERCIAL AND OPERATIONAL UPDATE

Patient Access and Commercial Pathway

EVE continued to develop its men's health patient access pathway, combining condition-focused information through LibX.com.au with telehealth services provided by hubMed and pharmacy fulfilment arrangements with Chemist2U. These arrangements are intended to support access to eligible patients through applicable Australian prescribing pathways, including the Special Access Scheme Category B (SAS-B), where the necessary patient-specific approvals are obtained. The pathway gives EVE an established patient acquisition model, telehealth prescribing workflow, pharmacy logistics and regulatory compliance processes, which the Company will continue to refine.

Libbo® Pilot Clinical Study and Regulatory Development

During the quarter, EVE continued preparations for a pilot pharmacokinetic study of its erectile dysfunction oral soluble film. The study will compare the film with a registered reference tablet in fasted healthy male participants and include assessments relevant to the film format. The Company is targeting commencement of dosing in Q4 2026, subject to completion of the remaining testing and regulatory steps, with results anticipated in early 2027. Findings are expected to inform the design of the pivotal bioequivalence study that

underpins the Company's registration pathway. Subject to satisfactory pilot outcomes, regulatory requirements and study readiness, EVE is targeting commencement of that study in Q1 2027 and a potential registration submission in the second half of 2027.

Erectile dysfunction represents a significant potential market for treatment options, with an estimated 322 million men worldwide affected by erectile dysfunction in 2025. EVE is developing an oral film as an alternative dosage format to existing tablet products. The Company considers that patient preferences and variability in response to currently available therapies may provide opportunities for differentiated delivery formats.

Reformulation Platform and Pipeline

EVE's reformulation platform supports a development pipeline spanning men's health and cardio-metabolic indications, consistent with its proposed partner-led commercial strategy. Earlier-stage men's health programs include premature ejaculation and a combined erectile dysfunction and premature ejaculation therapy. Cardio-metabolic work includes an apixaban anticoagulation reformulation program in pre-bioequivalence development and exploratory lipid-lowering programs involving rosuvastatin and atorvastatin. The Company continues to evaluate potential reformulation candidates, with development progress and commercial opportunities subject to further technical assessment and partner engagement.

Dyspro® Women's Health Program

During the quarter, EVE continued work relating to Dyspro®, its women's health product, including the preparation of a case study report examining patient experiences. The report is being progressed and is expected to inform the Company's assessment of future development and commercialisation activities.

Meluka Australia

Meluka Australia continued to generate sales through its online consumer health business during the quarter. Trading strengthened month by month, supported by sales of its established product range and purchasing by returning customers. The Company remains focused on maintaining its direct-to-consumer channels and existing customer relationships.

FUTURE OUTLOOK

— EVE expects dosing in its erectile dysfunction oral film pilot study to commence in Q4 2026, with pilot data anticipated in early 2027.

— Subject to satisfactory pilot outcomes and study readiness, the Company intends to advance its oral film into a proposed pivotal bioequivalence study, currently targeted to commence in Q1 2027.

— Subject to successful completion of the necessary clinical and regulatory work, EVE intends to pursue a product registration submission following the pivotal study.

— EVE will continue assessing its broader reformulation pipeline and associated intellectual property, including earlier-stage men's health, anticoagulation and lipid-lowering programs.

— The Company will continue exploring potential licensing, supply and development arrangements with pharmaceutical partners in international markets. Discussions remain preliminary and there is no assurance that they will result in binding agreements.

— The Company expects to finalise its Research and Development Tax Incentive claim for the year ended 30 June 2026 and receive a cash refund under the programme in the December quarter.

Commenting on the quarter, Chief Executive Officer Mr Ben Rohr said: *"During the quarter, we continued to build the patient access arrangements for our oral film program and prepare for the next stage of clinical development. Our priorities are to progress the pilot study, use its findings to inform subsequent development and advance selected opportunities across our reformulation pipeline."*

This announcement has been authorised for release by the Board of EVE Health Group Limited.

PAYMENTS TO RELATED PARTIES

Payments to related parties and their associates during the quarter, as disclosed in item 6.1 of the accompanying Appendix 4C, totalled $67,000, comprising $64,000 in directors' fees and $3,000 in office overheads paid to Mitchell River Group Pty Ltd.

ANNOUNCEMENTS RELEASED DURING THE QUARTER

DATE	ANNOUNCEMENT
31 August 2026	Annual Report to Shareholders (including Appendix 4E)
3 September 2026	Release of Securities from Escrow
22 September 2026	Date of AGM and Closing Date for Director Nominations
22 September 2026	Investor Presentation — Coffee Microcaps Conference

FOR MORE INFORMATION, PLEASE CONTACT

COMPANY ENQUIRIES
+61 8 6465 5500
info@evehealthgroup.com.au

INVESTOR RELATIONS AND MEDIA
Peter Taylor
peter@nwrcommunications.com.au

ABOUT EVE HEALTH GROUP

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The Company's lead assets include a fast-acting pastille targeting dysmenorrhoea and endometriosis, and an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both assets leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and LibX.com.au (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
EVE Health Group Limited	
ABN	**Quarter ended ("current quarter")**
89 106 523 611	30 September 2026

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	208	208
1.2	Payments for		
	a) research and development	(22)	(22)
	b) product manufacturing and operating costs	(111)	(111)
	c) advertising and marketing	(215)	(215)
	d) leased assets	-	-
	e) staff costs	(174)	(174)
	f) administration and corporate costs	(95)	(95)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	8	8
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(402)**	**(402)**
2.	**Cash flows from investing activities**		
2.1	Payments to or for acquire:		
	a) entities	-	-
	b) businesses	-	-
	c) property, plant and equipment	-	-
	d) investments	-	-
	e) intellectual property	-	-
	f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	a) entities	-	-
	b) businesses	-	-
	c) property, plant and equipment	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	d) investments	-	-
	e) intellectual property	-	-
	f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**-**	**-**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,238	1,238
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(402)	(402)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**836**	**836**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	686	538
5.2	Call deposits	150	700
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**836**	**1,238**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	67
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**		
7.5	**Unused financing facilities available at quarter end**		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	-		

8.	Estimated cash available for future operating activities	$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(402)
8.2	Cash and cash equivalents at quarter end (item 4.6)	836
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	836
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	2.1
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.	

8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
	Answer: N/A	
	8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
	Answer: N/A	
	8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	Answer: N/A	
	Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.	

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2026

Authorised by: Steven Jackson, Company Secretary
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.